时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
However, the vast majority of patients will still recur (, ), accompanied by platinum resistance.；However, no direct evidence has demonstrated the relation of M2d TAMs and ApoE in cisplatin resistance in OC to date.
方法
A 10 μl reverse transcription reaction system was prepared following the manufacturer’s instructions for the Bestar qPCR RT Kit.；The system contained DBI Bestar® SybrGreen qPCR MasterMix.；The sequences of all indicated primers were listed in , and representative RT-qPCR amplification curves and melting-curve analysis were shown in .；Dehydration was performed through a graded ethanol series. 75% ethanol for 4 h, 85% ethanol for 2 h, 90% ethanol for 2 h, 95% ethanol for 1 h, absolute ethanol twice for 30 min each, followed by absolute ethanol and xylene for 5–10 min each.
核心结论
Elevated proliferation was observed in cisplatin-exposed OC cells upon M2d TAMs treatment or ApoE overexpression, which further verified the development of cisplatin resistance.；Taken together, xenograft model results demonstrated that M2d TAMs and ApoE overexpression facilitate the proliferation of OC xenografts in vivo, and might further confer chemoresistance to cisplatin in OC cells.；For M2d TAMs or Lv-ApoE groups, the cells were regularly arranged, the degree of necrosis was mild, no obvious tissue damage was observed, and the cell number was markedly elevated compared to control groups, respectively. ‖ 结论：Moreover, exosomal ApoE levels in ascites or plasma, together with M2d-specific gene expression in tumor tissues, could serve as novel biomarkers for predicting platinum chemosensitivity and evaluating prognosis in OC patients.
局限
Importantly, we also acknowledge that the potential contributions of other uninvestigated cell types cannot be excluded ().
对本项目的价值
★☆☆☆☆ 相关范围内，作为背景与横向对照收录。
全文来源
PMC JATS 全文（正文 26,974 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Regulatory mechanism of M2d tumor-associated macrophage-derived exosomal apolipoprotein E on platinum resistance in ovarian cancer.
- 期刊与标识：Front Oncol · PMID 42959057 · DOI 10.3389/fonc.2026.1946625
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。